IRIS
CESARO, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.048
EU - Europa 6.641
AS - Asia 3.387
SA - Sud America 523
Continente sconosciuto - Info sul continente non disponibili 296
AF - Africa 61
OC - Oceania 6
Totale 17.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.895
RU - Federazione Russa 4.808
SG - Singapore 1.214
CN - Cina 718
IT - Italia 710
VN - Vietnam 529
IE - Irlanda 487
HK - Hong Kong 436
BR - Brasile 412
GB - Regno Unito 167
DE - Germania 162
KR - Corea 149
IN - India 126
CA - Canada 71
AR - Argentina 48
BD - Bangladesh 46
FR - Francia 45
MX - Messico 36
AT - Austria 31
JP - Giappone 31
GR - Grecia 27
UA - Ucraina 27
NL - Olanda 24
SE - Svezia 24
ES - Italia 23
FI - Finlandia 23
CO - Colombia 22
ID - Indonesia 21
TR - Turchia 21
PL - Polonia 18
BE - Belgio 16
EG - Egitto 16
IQ - Iraq 14
JM - Giamaica 13
LT - Lituania 13
PK - Pakistan 12
EC - Ecuador 11
MA - Marocco 11
ZA - Sudafrica 11
CR - Costa Rica 10
VE - Venezuela 10
CL - Cile 7
EE - Estonia 6
PH - Filippine 6
SA - Arabia Saudita 6
TH - Thailandia 6
TN - Tunisia 6
UZ - Uzbekistan 6
IL - Israele 5
IR - Iran 5
KZ - Kazakistan 5
BG - Bulgaria 4
CH - Svizzera 4
DK - Danimarca 4
JO - Giordania 4
MY - Malesia 4
NP - Nepal 4
PA - Panama 4
TW - Taiwan 4
UY - Uruguay 4
AU - Australia 3
AZ - Azerbaigian 3
BS - Bahamas 3
KE - Kenya 3
NZ - Nuova Zelanda 3
PE - Perù 3
PR - Porto Rico 3
PY - Paraguay 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
EU - Europa 2
GY - Guiana 2
HN - Honduras 2
KG - Kirghizistan 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
Totale 17.659
Salva come PNG Salva come JPEG
Città #
Moscow 1.761
San Jose 729
Singapore 575
Ashburn 499
Dublin 476
Hong Kong 428
Santa Clara 399
Council Bluffs 330
Chandler 237
Ho Chi Minh City 176
Hefei 170
New York 145
Seoul 145
Hanoi 130
Milan 127
Los Angeles 112
Beijing 99
Dallas 94
Naples 93
The Dalles 83
Atlanta 69
Bengaluru 68
Princeton 64
Roxbury 51
San Francisco 44
Jacksonville 43
Da Nang 41
Orem 36
Rome 36
Bremen 34
Nuremberg 34
North Bergen 33
Cambridge 30
Phoenix 30
São Paulo 30
Denver 29
Brooklyn 24
Des Moines 24
Medford 23
Memphis 22
Falkenstein 21
Munich 20
Boardman 19
Mexico City 19
Haiphong 18
Kochi 18
Miano 18
Toronto 18
Tokyo 17
Brussels 16
Chicago 16
Frankfurt am Main 15
Montreal 15
Aversa 14
Rio de Janeiro 14
Helsinki 13
Houston 13
Ann Arbor 12
Hyderabad 12
Vienna 12
Bari 11
Guangzhou 11
London 11
Turin 11
Wilmington 11
Brasília 10
Hải Dương 10
Nanjing 10
Warsaw 10
Amsterdam 9
Bologna 9
Cairo 9
Thái Nguyên 9
Belo Horizonte 8
Boston 8
Campinas 8
Curitiba 8
Ercolano 8
Nha Trang 8
Ninh Bình 8
San José 8
Shenzhen 8
Sivas 8
Thái Bình 8
Buffalo 7
Caserta 7
Dhaka 7
Florence 7
Jakarta 7
Jinan 7
Seattle 7
The Bronx 7
Baghdad 6
Brescia 6
Buenos Aires 6
Can Tho 6
Columbus 6
Kingston 6
Madrid 6
Miami 6
Totale 8.216
Salva come PNG Salva come JPEG
Nome #
The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: A systematic review and meta-analysis of randomized clinical studies 2.608
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials 336
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 282
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 270
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 269
The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota 200
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 191
Advanced Heart Failure in Special Population—Pediatric Age 187
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 185
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 175
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 171
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 171
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis 163
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease 163
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 160
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 158
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 153
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 151
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 149
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 146
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 145
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes 145
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 144
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 144
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 142
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 142
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 141
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 141
The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases 140
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque 138
Ipercolesterolemia e referti di laboratorio: documento congiunto della Società Italiana di Cardiologia (SIC) e Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio (SIBioC) 138
Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy 137
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 135
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 135
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge 135
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes 135
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 133
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 133
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 131
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 131
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 130
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach 130
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 130
Circulating culprit or therapeutic bullseye: lipoprotein(a) in cardiovascular risk assessment and novel therapeutic prospects 124
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 122
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 120
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 120
SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction 120
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 119
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 118
A pragmatic approach for thrombotic prevention after acute coronary syndromes 117
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review 117
Early-onset MINOCA: Prognostic implications and considerations for practice 116
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 114
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent 113
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 113
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 112
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 111
Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference 111
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 110
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT) 110
Coronary stent thickness: thinner is (always) better for all lesions? 109
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 109
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 109
Epigenetic mechanisms underlying the beneficial effects of cardiac rehabilitation. An overview from the working groups of “cellular and molecular biology of the heart” and “cardiac rehabilitation and cardiovascular prevention” of the Italian Society of Cardiology (SIC) 108
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 108
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 108
[Long COVID: nosographic aspects and clinical epidemiology] 107
Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): A meta-analysis 107
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 106
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 106
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 105
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 104
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol 104
Artificial intelligence in cardiovascular prevention: new ways will open new doors 103
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 103
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? 102
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 101
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 100
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 100
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 100
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 99
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 98
The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers 98
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 98
How has COVID-19 impacted the care of patients with acute coronary syndromes? 97
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 97
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 96
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 96
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? 95
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 95
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 94
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia 93
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 93
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 93
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey 90
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 89
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial 89
Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention 87
Laboratory medicine: health evaluation in elite athletes 87
Totale 15.413
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.486
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.486
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022410 0 0 0 17 104 10 10 41 9 55 37 127
2022/2023863 84 56 19 59 77 46 2 57 428 5 14 16
2023/2024513 28 17 20 24 129 111 19 12 4 29 13 107
2024/20251.804 8 13 2 54 251 207 231 170 259 276 172 161
2025/20269.130 359 526 487 415 671 4.519 603 584 361 293 179 133
2026/20274.962 2.486 997 764 715 0 0 0 0 0 0 0 0
Totale 17.962